touchCARDIO spoke to Dr Duk-Woo Park (Asan Medical Center, Seoul, South Korea) to discuss his presentation at the American College of Cardiology Annual Meeting 2022, providing the results of the ADAPT-TAVR trial of edoxaban versus dual antiplatelet therapy for valve thrombosis and cerebral thromboembolism after transcatheter aortic-valve replacement. (To view Part One click here)
Questions
- What were the aims and design of the ADAPT-TAVR study? 00:20-01:33
- What were the efficacy and findings of the study? 01:33-02:34
- What were the conclusions of the investigators regarding future clinical practice? 02:34-03:40
Speaker Disclosure: Duk-Woo Park discloses institutional research grants from Boston scientific, Abbott and Philips.
Support: Interview and filming supported by Touch Medical Media Ltd. Interview conducted by Sophie Nickelson.
Filmed in coverage of the American College of Cardiology Annual Meeting 2022
